Eli Lilly acquires Verve Therapeutics in a landmark $1 billion agreement that could reshape the treatment landscape for heart disease. This move underscores the pharmaceutical giant’s commitment to investing in one-time gene therapies that replace chronic care models.
Announced on June 17, 2025, the deal includes a $10.50 per share cash buyout for all outstanding Verve stock, totaling $1 billion upfront. An additional $300 million may follow if Verve’s flagship therapy meets key clinical milestones — bringing the full value of the deal to $1.3 billion, according to The Wall Street Journal.
One Shot, Long-Term Impact
At the heart of this acquisition lies Verve-102, a cutting-edge in vivo gene-editing therapy targeting the PCSK9 gene, which plays a critical role in cholesterol regulation and heart disease. Unlike daily pills or injections, Verve-102 aims to deliver a “one-and-done” treatment, potentially transforming how millions manage their cardiovascular health.
The drug is currently in Phase 1b clinical trials and has been granted fast-track designation by the U.S. Food and Drug Administration, highlighting its potential to address urgent medical needs.
Why This Matters
“This could be the first in vivo gene-editing treatment for a broad population,” said Ruth Gimeno, Lilly’s VP of metabolic and diabetes R&D. “It’s a major shift in how we think about treating cardiovascular disease.”
If Verve-102 reaches Phase 3 trials and the first patient is dosed within 10 years of the deal’s close, Verve shareholders will receive an extra $3 per share — a significant incentive tied to future clinical progress.
Verve’s Bold Mission
Founded just seven years ago, Verve Therapeutics has made remarkable progress in gene-editing therapies. The company has advanced three in vivo editing candidates, with two already in human trials.
“We set out to change how heart disease is treated,” said Dr. Sekar Kathiresan, co-founder and CEO of Verve. “Now, joining forces with Lilly gives us the resources to go even further.”
What’s Next?
Lilly plans to finalize the acquisition by Q3 2025, pending shareholder approval and regulatory clearance.
This deal marks another major step in the growing race to commercialize next-generation gene therapies. As major pharmaceutical players like Lilly move beyond maintenance drugs, the future of medicine may lie in curative, single-dose treatments.
Explore More
- Learn about the science behind gene editing and PCSK9
- Catch up on other biotech mergers and acquisitions
